%0 Journal Article
%A Makhov, V. N.
%A Kirm, M.
%A Stryganyuk, G.
%A Vielhauer, S.
%A Zimmerer, G.
%A DESY
%T VUV luminescence due to 5d-4f transitions in Gd<sup>3+</sup> and Lu<sup>3+</sup> ions doped into fluoride crystals
%J ECS transactions
%V 11
%@ 1938-5862
%C Pennington, NJ
%I Electrochemical Society (ECS)
%M PHPPUBDB-8392
%P 1-10
%D 2008
%X This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0
%K Adolescent
%K Adult
%K Anticonvulsants: therapeutic use
%K Child
%K Child, Preschool
%K Double-Blind Method
%K Drug Evaluation
%K Drug Therapy, Combination: methods
%K Epilepsy: drug therapy
%K Female
%K Humans
%K Longitudinal Studies
%K Male
%K Treatment Outcome
%K Triazoles: therapeutic use
%K Young Adult
%K Anticonvulsants (NLM Chemicals)
%K Triazoles (NLM Chemicals)
%K rufinamide (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:20199521
%U <Go to ISI:>//WOS:00
%R 10.1149/1.2929812
%U https://bib-pubdb1.desy.de/record/84831